Business · Companies · 7 hrs ago
Indira IVF in talks to buy Kerala hospital chain Sabine
Indira IVF is in talks to acquire Sabine Hospital and Research Centre, a healthcare chain based in Kerala.
The proposed deal could value Sabine at ₹1,200-1,300 crore, and Indira IVF may buy a 70-75% stake.
Sabine has two facilities offering fertility treatment, childbirth, newborn care and other gynaecological services.
It operates 300 beds and carries out more than 6,000 IVF cycles and 3,000 deliveries each year.
The purchase would strengthen Indira IVF's presence in India's fertility treatment market, where it has made several acquisitions in recent years.
The company is also preparing for a ₹3,500-crore initial public offering.
The discussions are ongoing, and no final deal has been announced.
Indira IVF is in discussions to acquire Kerala-based Sabine Hospital and Research Centre, according to people cited by the Economic Times.
The proposed deal could value Sabine at ₹1,200-1,300 crore.
Indira IVF is likely to acquire a 70-75% stake, including additional shares from Sabine’s founder.
Sabine operates two facilities in Kerala that provide fertility, maternal and other healthcare services.
The acquisition would strengthen Indira IVF’s position in India’s fertility treatment market.
- Who
- Indira IVF and Sabine Hospital and Research Centre.
- What
- They are in discussions about a proposed acquisition of Sabine. Indira IVF is likely to buy a 70-75% stake.
- When
- The report was published on October 27, 2026. The sources do not state when a deal might be completed.
- Where
- Sabine operates two facilities in Kerala, India.
- Why
- The acquisition would strengthen Indira IVF’s position in India’s fertility treatment market.
This story does not have two clearly opposing sides.
Sabine Hospital and Research Centre was founded by Dr Sabine Sivadasan.
CX Partners acquired about 54% of Sabine at a valuation of $100 million, or about ₹835 crore.
The Economic Times reported that Indira IVF was in discussions to acquire Sabine.
- Proposed valuation
- ₹1,200-1,300 crore
- Likely stake
- 70-75%
- Facilities
- Two in Kerala
- Capacity
- 300 beds, including 60 neonatal intensive care unit beds
- Projected FY27 revenue
- ₹230-250 crore